• Je něco špatně v tomto záznamu ?

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

C. Buske, MA. Dimopoulos, A. Grunenberg, E. Kastritis, C. Tomowiak, B. Mahé, X. Troussard, R. Hajek, A. Viardot, O. Tournilhac, T. Aurran, S. Lepretre, H. Zerazhi, B. Hivert, V. Leblond, S. de Guibert, L. Brandefors, R. Garcia-Sanz, M. Gomes da...

. 2023 ; 41 (14) : 2607-2616. [pub] 20230210

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011460

PURPOSE: Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety of dexamethasone, rituximab, and cyclophosphamide (DRC) as first-line treatment in WM. METHODS: In this European study, treatment-naïve patients were randomly assigned to DRC or bortezomib-DRC B-DRC for six cycles. The primary end point was progression-free survival. Secondary end points included response rates, overall survival, and safety. RESULTS: Two hundred four patients were registered. After a median follow-up of 27.5 months, the estimated 24-month progression-free survival was 80.6% (95% CI, 69.5 to 88.0) for B-DRC and 72.8% (95% CI, 61.3 to 81.3) for DRC (P = .32). At the end of treatment, B-DRC and DRC induced major responses in 80.6% versus 69.9% and a complete response/very good partial response in 17.2% versus 9.6% of patients, respectively. The median time to first response was shorter for B-DRC with 3.0 (95% CI, 2.8 to 3.2) versus 5.5 (95% CI, 2.9 to 5.8) months for DRC. This resulted in higher major response rates (57.0% v 32.5%; P < .01) after three cycles of B-DRC compared with DRC. At best response, the complete response/very good partial response increased to 32.6% for B-DRC. Both treatments were well tolerated: grade ≥ 3 adverse events occurred in 49.2% of all patients (B-DRC, 49.5%; DRC, 49.0%). Peripheral sensory neuropathy grade 3 occurred in two patients treated with B-DRC and in none with DRC. CONCLUSION: This large randomized study illustrates that B-DRC is highly effective and well tolerated in WM. The data demonstrate that fixed duration immunochemotherapy remains an important pillar in the clinical management of WM.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011460
003      
CZ-PrNML
005      
20230801133046.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.22.01805 $2 doi
035    __
$a (PubMed)36763945
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Buske, Christian $u Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany $1 https://orcid.org/0000000297829012
245    10
$a Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia / $c C. Buske, MA. Dimopoulos, A. Grunenberg, E. Kastritis, C. Tomowiak, B. Mahé, X. Troussard, R. Hajek, A. Viardot, O. Tournilhac, T. Aurran, S. Lepretre, H. Zerazhi, B. Hivert, V. Leblond, S. de Guibert, L. Brandefors, R. Garcia-Sanz, M. Gomes da Silva, E. Kimby, B. Schmelzle, D. Kaszynski, J. Dreyhaupt, R. Muche, P. Morel
520    9_
$a PURPOSE: Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety of dexamethasone, rituximab, and cyclophosphamide (DRC) as first-line treatment in WM. METHODS: In this European study, treatment-naïve patients were randomly assigned to DRC or bortezomib-DRC B-DRC for six cycles. The primary end point was progression-free survival. Secondary end points included response rates, overall survival, and safety. RESULTS: Two hundred four patients were registered. After a median follow-up of 27.5 months, the estimated 24-month progression-free survival was 80.6% (95% CI, 69.5 to 88.0) for B-DRC and 72.8% (95% CI, 61.3 to 81.3) for DRC (P = .32). At the end of treatment, B-DRC and DRC induced major responses in 80.6% versus 69.9% and a complete response/very good partial response in 17.2% versus 9.6% of patients, respectively. The median time to first response was shorter for B-DRC with 3.0 (95% CI, 2.8 to 3.2) versus 5.5 (95% CI, 2.9 to 5.8) months for DRC. This resulted in higher major response rates (57.0% v 32.5%; P < .01) after three cycles of B-DRC compared with DRC. At best response, the complete response/very good partial response increased to 32.6% for B-DRC. Both treatments were well tolerated: grade ≥ 3 adverse events occurred in 49.2% of all patients (B-DRC, 49.5%; DRC, 49.0%). Peripheral sensory neuropathy grade 3 occurred in two patients treated with B-DRC and in none with DRC. CONCLUSION: This large randomized study illustrates that B-DRC is highly effective and well tolerated in WM. The data demonstrate that fixed duration immunochemotherapy remains an important pillar in the clinical management of WM.
650    _2
$a lidé $7 D006801
650    _2
$a rituximab $7 D000069283
650    12
$a Waldenströmova makroglobulinemie $x farmakoterapie $7 D008258
650    _2
$a bortezomib $x škodlivé účinky $7 D000069286
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a cyklofosfamid $7 D003520
650    _2
$a dexamethason $7 D003907
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece $1 https://orcid.org/0000000189903254
700    1_
$a Grunenberg, Alexander $u Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
700    1_
$a Kastritis, Efstathios $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece $1 https://orcid.org/0000000181915832
700    1_
$a Tomowiak, Cecile $u Hematology Department and CIC1402 INSERM, CHU Poitiers, Poitiers, France $1 https://orcid.org/0000000340936463
700    1_
$a Mahé, Béatrice $u CHU-Hôtel Dieu, Nantes, France
700    1_
$a Troussard, Xavier $u CHU Cote de Nacre/Hopital de Caen, Caen, France $1 https://orcid.org/0000000168639992
700    1_
$a Hajek, Roman $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
700    1_
$a Viardot, Andreas $u Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
700    1_
$a Tournilhac, Olivier $u CHU Estaing, Clermont-Ferrand, France $1 https://orcid.org/000000029438621X
700    1_
$a Aurran, Therese $u Hematology Department, Institut Paoli-Calmettes, Marseille France
700    1_
$a Lepretre, Stephane $u Inserm U1245 and Department of Hematology, Centre Henri Becquerel and Normandie Univ UNIROUEN, Rouen, France
700    1_
$a Zerazhi, Hacene $u CH Avignon, Avignon, France $1 https://orcid.org/0000000346394191
700    1_
$a Hivert, Benedicte $u Centre Hospitalier Schaffner, Lens Cedex 9, Lens Cedex, France
700    1_
$a Leblond, Veronique $u Sorbonne Université. Hématologie clinique Hôpital Pitié Salpêtrière. APHP, Paris, France
700    1_
$a de Guibert, Sophie $u CHU Pontchaillou, Rennes, France
700    1_
$a Brandefors, Lena $u Sunderby Sjukhus, Luleå, Sweden $1 https://orcid.org/0000000307651685
700    1_
$a Garcia-Sanz, Ramon $u Hospital Universitario de Salamanca, Salamanca, Spain $1 https://orcid.org/0000000341202787
700    1_
$a Gomes da Silva, Maria $u Instituto Português de Oncologia de Lisboa, Lisbon, Portugal $1 https://orcid.org/0000000269932450
700    1_
$a Kimby, Eva $u Department of Medicine Huddinge, Karolinska Institutet, Unit for Hematology, Stockholm, Sweden $1 https://orcid.org/0000000330786131
700    1_
$a Schmelzle, Birgit $u Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany
700    1_
$a Kaszynski, Dajana $u Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany
700    1_
$a Dreyhaupt, Jens $u Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
700    1_
$a Muche, Rainer $u Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
700    1_
$a Morel, Pierre $u CHU Amiens Hôpital Sud, Amiens, France $1 https://orcid.org/0000000207823144
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 41, č. 14 (2023), s. 2607-2616
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36763945 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133043 $b ABA008
999    __
$a ok $b bmc $g 1963708 $s 1197725
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 41 $c 14 $d 2607-2616 $e 20230210 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace